Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer

Recruiting

• Conditions: Sarcoma

• Registration Number: NCT01831609
• Lead Sponsor: Samsung Medical Center

Brief Summary

To prospectively collect ascites, pleural fluid, circulating tumor cells and derived primary cultures from metastatic cancer patients. The specimens will be analyzed using DNA/RNA/proteomic approaches.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2011-08-31
• Study First Submitted: 2013-04-07
• Study First Submitted QC: 2013-04-12
• Study First Posted: 2013-04-15
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-13
• Last Update Posted: 2022-06-15
• Primary Completion: 2023-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare cancer
2. Written informed consent
3. body fluid derived from cancer, available for drainage and collection

Read More

Exclusion Criteria

• patients who do not give informed consent form for research use of biomaterials/biospecimens

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biomarker analyses to predict treatment response in metastatic cancer	3 year	Using patient derived tumor cells, predictive biomarker analyses (DNA, RNA protein levels etc) will be assessed.

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of